Am J Leuk Res | Volume 2, Issue 1 | Case Report | Open Access

Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with Azacitidne

Irina Panovska-Stavridis^1*, M Ivanovski¹, S.Trajkova¹, A Pivkova-Veljanovska¹, M PopovaLabaceska¹, N Matevska-Geshovska², P Noveski³, D Plaseska-Karanfilska³, L Cevreska¹ and AJ Dimovski²

¹Department of Medicine, University Clinic of Hematology, Skopje
²Department of Pharmacy, Center of Biomolecular Pharmaceutical Analyses, Skopje
³Department of Engineering, Research Centre for Genetic Engineering and Biotechnology, Skopje

^*Correspondance to: Irina Panovska-Stavridis 

Fulltext PDF

Abstract

Myelodysplastic Syndrome (MDS) is a diverse group of clonal hematologic neoplasms. The only curative treatment for MDS is allogeneic Stem Cell Transplantation (SCT). Epigenetic changes play an important role in the pathogenesis of MDS and treatment with DNA methyl transferase inhibitors, Azacitidine significantly prolong the survival of high-risk MDS patients.

Citation:

Panovska-Stavridis I, Ivanovski M, Trajkova S, Pivkova-Veljanovska A, Popova-Labaceska M, MatevskaGeshovska N, et al. Moleculary Confirmed, Cytogenetic Remission in a Case with Myelodysplastic Syndrome Treated with zacitidne. Am J Leuk Res. 2018;2(1):1008.